The Biotech Value Play: Cephalon
The company guided towards $7-7.20 for 2010 yet the market continued to sell the stock down into the upper $50s or below 9x guidance. Its interesting that the current highest estimate is only $6.98. Analysts apparently doubt the guidance.
Though trading below the 200EMA is concerning from a technical basis. Today's weak bounce means the stock is likely to lag any rebound in the market. If it doesn't hold, we made trade it for a lower entry. The value thesis just becomes more attractive at lower prices.